Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Article Type
Facet Toggle
Time Frame
Facet Toggle
WORKING PAPERS
October 11, 2023
Many countries are facing a much harsher budgetary prospect than a few years ago. For low- and middle-income countries in particular, domestic health expenditure is expected to plateau or contract (in real terms) for many until 2027, development assistance for health has already plateaued, and a deb...
Blog Post
October 11, 2023
Prior to the COVID-19 pandemic there were periods of sustained growth in many low- and middle-income countries that led to some optimism about countries “transitioning” from (i.e. no longer being eligible for) support from the major global health financing mechanisms, such as the Global Fund, Gavi, ...
Blog Post
September 27, 2023
The UK is, hopefully, coming out of its nadir in international development. This is marked by planned rises in development spend, an ambitious new international development white paper, a supportive Minister, and a new parliament in 2024. But before considering any proposal, future governments with ...
Blog Post
September 19, 2023
Health systems in Africa are under considerable strain: rapid demographic change, rising non-communicable diseases, and emerging and re-emerging threats such as COVID-19 and Ebola are increasing demands on limited health services. The African Union’s admission to the G20 provides an opportunity for ...
Blog Post
September 05, 2023
Today the Africa Centers for Disease Control’s (ACDC) Health Economics Programme (HEP) has published a new policy brief on the cost-effectiveness of two COVID-19 oral antivirals (COAVs), a nirmatrelvir/ritonavir combination, developed by Pfizer and sold under the name Paxlovid, and Molnupiravir, dev...
Blog Post
August 22, 2023
A recent, thought-provoking blog by our colleague, Justin Sandefur, titled “How Economists got Africa’s AIDS Epidemic Wrong”, has sparked a debate about the historical role of cost-effectiveness analysis in assessing the investments of the President's Emergency Plan for AIDS Relief (PEPFAR) and, imp...